TRPV4 channels regulate tumor angiogenesis via modulation of Rho/Rho kinase pathway

Oncotarget

Volumn 7, Issue 18, 2016, Pages 25849-25861

  Thoppil, Roslin J ^a,b   Cappelli, Holly C ^a,b   Adapala, Ravi K ^a,b   Kanugula, Anantha K ^a   Paruchuri, Sailaja ^c   Thodeti, Charles K ^a,b  

^a Northeast Ohio Medical University   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c UNIVERSITY OF AKRON   (United States)

Author keywords

Endothelial cell; Mechanotransduction; Rho Rho kinase; TRPV4; Tumor angiogenesis

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CISPLATIN; RHO FACTOR; RHO KINASE; VANILLOID RECEPTOR 4; TRPV4 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME REGULATION; EX VIVO STUDY; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LEWIS CARCINOMA; MECHANOTRANSDUCTION; MOUSE; NONHUMAN; PERICYTE; PROTEIN DEPLETION; PROTEIN FUNCTION; REGULATORY MECHANISM; TUBE FORMATION; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CELL MOTION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; ENDOTHELIAL CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; RHO-ASSOCIATED KINASES; TRPV CATION CHANNELS;

EID: 84966728313     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8405     Document Type: Article

References (67)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653-660.
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473:298-307.
4. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010; 17:206-225.
5. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews Cancer. 2008; 8:592-603.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer cell. 2005; 8:299-309.
7. Fiorio Pla A, Gkika D. Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. Front Physiol. 2013; 4:311.
8. Lehen'kyi V, Prevarskaya N. (2011). Study of TRP Channels in Cancer Cells. In: Zhu MX, ed. TRP Channels. (Boca Raton (FL).
9. Lehen'kyi V, Prevarskaya N. Oncogenic TRP channels. Advances in experimental medicine and biology. 2011; 704:929-945.
10. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nature reviews Cancer. 2011; 11:609-618.
11. Shapovalov G, Lehen'kyi V, Skryma R, Prevarskaya N. TRP channels in cell survival and cell death in normal and transformed cells. Cell calcium. 2011; 50:295-302.
12. Adapala RK, Thoppil RJ, Ghosh K, Cappelli HC, Dudley AC, Paruchuri S, Keshamouni V, Klagsbrun M, Meszaros JG, Chilian WM, Ingber DE, Thodeti CK. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene. 2015.
13. Earley S, Pauyo T, Drapp R, Tavares MJ, Liedtke W, Brayden JE. TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure. Am J Physiol Heart Circ Physiol. 2009; 297:H1096-1102.
14. Hartmannsgruber V, Heyken WT, Kacik M, KaisthaA, Grgic I, Harteneck C, Liedtke W, Hoyer J, Kohler R. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PloS one. 2007; 2:e827.
15. Kohler R, Heyken WT, Heinau P, Schubert R, Si H, Kacik M, Busch C, Grgic I, Maier T, Hoyer J. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilatation. Arterioscler Thromb Vasc Biol. 2006; 26:1495-1502.
16. Liedtke W. TRPV channels' role in osmotransduction and mechanotransduction. Handb Exp Pharmacol. 2007; 473-487.
17. Matthews BD, Thodeti CK, Tytell JD, Mammoto A, Overby DR, Ingber DE. Ultra-rapid activation of TRPV4 ion channels by mechanical forces applied to cell surface beta1 integrins. Integr Biol (Camb). 2010; 2:435-442.
18. Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R, Suzuki M, Zhang DX. TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol. 2010; 298:H466-476.
19. Thodeti CK, Matthews B, Ravi A, Mammoto A, GhoshK, Bracha AL, Ingber DE. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circulation research. 2009; 104:1123-1130.
20. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO reports. 2012; 13:900-908.
21. Nakabayashi H, Shimizu K. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer science. 2011; 102:393-399.
22. Nakajima M, Hayashi K, Katayama K, Amano Y, EgiY, Uehata M, Goto N, Kondo T. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. European journal of pharmacology. 2003; 459:113-120.
23. Ogata S, Morishige K, Sawada K, Hashimoto K, Mabuchi S, Kawase C, Ooyagi C, Sakata M, Kimura T. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. International journal of gynecological cancer. 2009; 19:1473-1480.
24. Patel RA, Liu Y, Wang B, Li R, Sebti SM. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene. 2014; 33:550-555.
25. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochemical and biophysical research communications. 2000; 269:652-659.
26. Teiti I, Florie B, Pich C, Gence R, Lajoie-MazencI, Rochaix P, Favre G, Tilkin-Mariame AF. In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression. Frontiers in oncology. 2015; 5:156.
27. Bryan BA, D'Amore PA. What tangled webs they weave: Rho-GTPase control of angiogenesis. Cellular and molecular life sciences. 2007; 64:2053-2065.
28. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, Takata K, Ohta T, Kawagoe J, Takahashi K, Kurachi H. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Molecular cancer therapeutics. 2007; 6:1517-1525.
29. Wermke M, Camgoz A, Paszkowski-Rogacz M, Thieme S, von Bonin M, Dahl A, Platzbecker U, Theis M, Ehninger G, Brenner S, Bornhauser M, Buchholz F. RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. Blood. 2015; 125:3760-3768.
30. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata Y, Dinter H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Molecular cancer therapeutics. 2006; 5:2158-2164.
31. Ingber DE. Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol. 1992; 3:57-63.
32. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circulation research. 2002; 91:877-887.
33. Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci U S A. 2008; 105:11305-11310.
34. Paszek MJ, Weaver VM. The tension mounts: mechanics meets morphogenesis and malignancy. Journal of mammary gland biology and neoplasia. 2004; 9:325-342.
35. Paszek MJ, Zahir N, Johnson KR, Lakins JN, RozenbergGI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM. Tensional homeostasis and the malignant phenotype. Cancer cell. 2005; 8:241-254.
36. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007; 13:223-230.
37. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69:11-16.
38. Munaron L. Intracellular calcium, endothelial cells and angiogenesis. Recent patents on anti-cancer drug discovery. 2006; 1:105-119.
39. Munaron L, Fiorio Pla A. Endothelial calcium machinery and angiogenesis: understanding physiology to interfere with pathology. Current medicinal chemistry. 2009; 16:4691-4703.
40. Munaron L, Genova T, Avanzato D, Antoniotti S, Fiorio Pla A. Targeting calcium channels to block tumor vascularization. Recent patents on anti-cancer drug discovery. 2013; 8:27-37.
41. Park YR, Chun JN, So I, Kim HJ, Baek S, Jeon JH, Shin SY. Data-driven Analysis of TRP Channels in Cancer: Linking Variation in Gene Expression to Clinical Significance. Cancer genomics & proteomics. 2016; 13:83-90.
42. Hamdollah Zadeh MA, Glass CA, Magnussen A, HancoxJC, Bates DO. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 2008; 15:605-614.
43. Jho D, Mehta D, Ahmmed G, Gao XP, Tiruppathi C, Broman M, Malik AB. Angiopoietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx. Circulation research. 2005; 96:1282-1290.
44. Yu PC, Gu SY, Bu JW, Du JL. TRPC1 is essential for in vivo angiogenesis in zebrafish. Circulation research. 2010; 106:1221-1232.
45. Ge R, Tai Y, Sun Y, Zhou K, Yang S, Cheng T, Zou Q, Shen F, Wang Y. Critical role of TRPC6 channels in VEGF-mediated angiogenesis. Cancer letters. 2009; 283:43-51.
46. Troidl C, Troidl K, Schierling W, Cai WJ, Nef H, Mollmann H, Kostin S, Schimanski S, Hammer L, Elsasser A, Schmitz-Rixen T, Schaper W. Trpv4 induces collateral vessel growth during regeneration of the arterial circulation. J Cell Mol Med. 2009; 13:2613-2621.
47. Kohler R, Hoyer J. Role of TRPV4 in the Mechanotransduction of Shear Stress in Endothelial Cells. In: Liedtke WB, Heller S, eds. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. (Boca Raton (FL). 2007.
48. Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology. 2010; 139:304-314 e302.
49. Zaika O, Mamenko M, Berrout J, Boukelmoune N, O'NeilRG, Pochynyuk O. TRPV4dysfunction promotes renal cystogenesis in autosomal recessive polycystic kidney disease. J Am Soc Nephrol. 2013; 24:604-616.
50. Thoppil RJ, Adapala RK, Cappelli HC, Kondeti V, Dudley AC, Gary Meszaros J, Paruchuri S, Thodeti CK. TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation. Scientific reports. 2015; 5:14257.
51. Kusuyama J, Bandow K, Shamoto M, Kakimoto K, Ohnishi T, Matsuguchi T. Low intensity pulsed ultrasound (LIPUS) influences the multilineage differentiation of mesenchymal stem and progenitor cell lines through ROCK-Cot/Tpl2-MEK-ERK signaling pathway. The Journal of biological chemistry. 2014; 289:10330-10344.
52. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508within the activation loop. The Journal of biological chemistry. 2000; 275:3577-3582.
53. Samarakoon R, Chitnis SS, Higgins SP, Higgins CE, Krepinsky JC, Higgins PJ. Redox-induced Src kinase and caveolin-1 signaling in TGF-beta1-initiated SMAD2/3 activation and PAI-1 expression. PloS one. 2011; 6:e22896.
54. Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, WallbergF, Viros A, Hooper S, Mitter R, Feral CC, CookM, Larkin J, Marais R, Meneguzzi G, et al. ROCK, JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer cell. 2011; 20:229-245.
55. Keely PJ. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. Journal of mammary gland biology and neoplasia. 2011; 16:205-219.
56. Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, Toulas C, Cohen-Jonathan-Moyal E. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene. 2003; 22:8861-8869.
57. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer biology & therapy. 2010; 9:875-884.
58. Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E, Kanayama M, Takahara S, Sugiyama T. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatology research. 2008; 38:810-817.
59. Davies PF, Spaan JA, Krams R. Shear stress biology of the endothelium. Ann Biomed Eng. 2005; 33:1714-1718.
60. Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM, Mostoslavsky G, Smith LE, Ingber DE. A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature. 2009; 457:1103-1108.
61. Mammoto A, Mammoto T, Ingber DE. Rho signaling and mechanical control of vascular development. Curr Opin Hematol. 2008; 15:228-234.
62. Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, Saint-Geniez M, Campaigniac JP, Liao JK, D'Amore PA. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEBJ. 2010; 24:3186-3195.
63. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer cell. 2012; 21:82-91.
64. Adapala RK, Talasila PK, Bratz IN, Zhang DX, Suzuki M, Meszaros JG, Thodeti CK. PKCalpha mediates acetylcholine-induced activation of TRPV4-dependent calcium influx in endothelial cells. Am J Physiol Heart Circ Physiol. 2011; 301:H757-765.
65. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nature protocols. 2012; 7:89-104.
66. Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J, Klagsbrun M. Calcification of multipotent prostate tumor endothelium. Cancer cell. 2008; 14:201-211.
67. Thodeti CK, Massoumi R, Bindslev L, Sjolander A. Leukotriene D4 induces association of active RhoA with phospholipase C-gamma1 in intestinal epithelial cells. Biochem J. 2002; 365:157-163.